Molecular changes during the genesis of human gliomas

Seminars in Surgical Oncology

Volumn 14, Issue 1, 1998, Pages 3-12

  Sehgal, Anil ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Astrocytoma; Brain neoplasms etiology; Chromosome deletion; genes; Gene deletion; Gene expression; Genome; Glioma; Human chromosomes; Mutation

Indexed keywords

CARCINOGENESIS; CHROMOSOME 10; CHROMOSOME 12Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 22Q; CHROMOSOME 7; CHROMOSOME 9P; GENE INSERTION; GENE LOCATION; GENE LOSS; GENE REARRANGEMENT; GLIOMA; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030778206     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199801/02)14:1<3::AID-SSU2>3.0.CO;2-F     Document Type: Article

References (83)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1996. ÇA Cancer J Clin 1996; 46:5-27.
2. Parker SL, Tong T, Bolden S, Wingo PA: Cancer statistics, 1997. ÇA Cancer J Clin 1997; 47:5-27.
3. Riggs JE: Rising primary malignant tumor mortality in the elderly. ArchNeurol 1995; 52:571-575.
4. Kleihues P, Soylemezoglu F, Schauble B, et al: Histopathology, classification, and grading of gliomas. Glia 1995; 15:211-221.
5. Kleihues P, Cavenee WK (eds): 'Tumours of the central nervous system: pathology and genetics'. Lyon, France: International Agency for Research on Cancer, 1997.
6. Von Diemling AV, Louis DN, Wiestier OD: Molecular pathways in the formation of gliomas. Glia 1995; 15:328-338.
7. Louis DN, von Deimling A, Dickersin GR, et al: Desmoplastic cerebral astrocytomas of infancy: a histopathologic, immunohistochemical, ultrastructural and molecular genetic study. Hum Pathol 1992; 23:1402-1409.
8. Fields C, Adams MD, White O, Venter JC: How many genes in the human genome? Nat Genet 1994; 7:345-346.
9. Adams MD, Kerlavage AR, Fields C, Venter JC: 3,400 new expressed sequence tags identify diversity of transcripts in human brain [comment in: Nat Genet 1994; 8:321-322]. Nat Genet 1993; 4:256-267.
10. Hunter T: Oncoprotein networks. Cell 1997; 88:333-346.
11. Tannock IF, Hill RP: "The basic science of oncology." New York: Pergamon Press; 1987.
12. Funari FB, Huang HS, Cavenee WK: Genetics and malignant progression of human brain tumors. Cancer Surv 1995; 25:233-275.
13. Zakut-Houri R, Bienz-Tadmor B, Givol D, Oren M: Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBOJ 1985; 4:1251-1255.
14. Eliyahu D, RazA, Grass P, et al: Participation of p53 cellulartumor antigen in transformation of normal embryonic cells. Nature 1984; 312(5995):646-649.
15. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244(4901):217-221.
16. Isobe M, Emanuel BS, Govol D, et al: Localization of gene for human p53 tumor antigen to band 17ql3. Nature 1986; 320(6057):84-85.
17. Bogler O, Huang HS, Kleiues P, Cavenee WK: The p53 gene and its role in human brain tumors [Review]. Glia:1995; 15:308-327.
18. Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers [Review]. Science 1991; 253(5015):49-53.
19. de Fromentel CC, Soussi T: TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992; 4:1-15.
20. Gomez-Mannnzano C, Fueyo J, Kyritsis AP, et al: Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 1996; 56:694699.
21. Westermark B, Heldin C, Nister M: Platelet-derived growth factor in human glioma. Glia 1995; 15:257-263.
22. Nister M, Claesson WL, Eriksson A, et al: Differential expression of platelet-derived growth factor receptors in human malignant glioma cell lines. J Biol Chem 1991; 266:16755-16763.
23. Hermanson M, Funa K, Hartman M, et al: Platelet-derived growth factor (PDGF) and its receptors in human glioma tissue: expression of mRNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 1992; 52:3213-3219.
24. Fults D, Pedone CA, Thomas GA, White R: Allelotype of human malignant astrocytoma. Cancer Res 1990; 50:5784-5789.
25. Rubio MP, Correa KM, Ramesh V, et al: Analysis of the neurofibromatosis 2 gene in human ependymonas and astrocytomas. Cancer Res 1994; 54:45-47.
26. Cavenee WK, Hansen MF, Nordenskjold M, et al: Genetic origin of mutations predisposing to retinoblastoma. Science 1985; 228(4698):501-503.
27. Beijersbergen RL, Bernards R: Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta 1996; 1287:103-120.
28. Wang NP, To H, Lee W, Lee E: Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 1993; 8:279-288.
29. TsuzukiT, Tsunoda S, SakakiT, et al: Alterations of retinoblastoma, p53, p!6(CDKN2), and p!5 genes in human astrocytomas. Cancer 1996; 78:287-293.
30. Louis DN, Gusella JF: A tiger behind many doors: multiple genetic pathways to malignant glioma. Trends Genet 1995; 11:412-415.
31. James CD, J H, Carlbom E, et al: Chromosome 9 deletion mapping reveals interferon alpha and interferon beta-lgene deletions in human glial tumors. Cancer Res 1991; 51:1684-1688.
32. Collins VP, James CD: Gene and chromosomal alterations associated with the development of human gliomas. FASEB J 1993; 7:926-930.
33. Minzuno M, Yoshida J, Sugita K, et al: Growth inhibition of glioma cells transfected wit the human beta-interferon gene by liposomes coupled wit a monoclonal antibody. Cancer Res 1990; 50:7826-7829.
34. Westermark B, NisterM: Molecular genetics of human glioma. Curr Opin Oncol 1995; 7: 220-225.
35. FoulkesWD, FlandersTY, PollockPM, HaywardNK:TheCDNK2A (p!6) gene and human cancer. Mol Med 1997; 3:5-20.
36. Schmidt EE, Ichimura K, Reifenberger G, Collins VP: CDNK2 (p 16/ MTS1 ) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res 1994; 54:6321-6324.
37. Jen J, Harper W, Bigner SH, et al: Deletion of pi 6 and p 15 genes in brain tumors. Cancer Res 1994; 54:6353-6358.
38. von Deimling A, Nagel J, Bender B, et al: Deletion mapping of chromosome 19 in human gliomas. Int J Cancer 1994; 57:676-680.
39. von Deimling A, Louis DN, von Ammon K, et al: Evidence for a tumor suppressor gene on chromosome arm 19q associated with human astrocytomas, oligodendrogliomas and mixed gliomas. Cancer Res. 1992; 52:4277-4279.
40. Collins VP: Gene amplification in human gliomas. Glia 1995; 15:289-296.
41. Reifenberger G, Reifenberger J, Ichimura K, et al: Amplification of multiple genes from chromosome region 12ql3-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994; 54:4299-4303.
42. Forus A, Myklebost O: A physical map of a 1.3-Mb region on the long arm of chromosome 12, spanning the GLI and LRP loci. Genomics 1992; 14:117-120.
43. Perhouse MA, Stubblefield E, Hadi A, et al: Analysis of the functional role of chromosome 10 loss in human glioblastomas. Cancer Res 1993; 53:5043-5050.
44. Venter DJ, Thimas DO: Multiple sequential molecular abnormalities in the evolution of human gliomas. Br J Cancer 1991; 8:753-757.
45. Steck PA, Ligon A, Cheong P, et al: Two tumor suppressive loci on chromosome 10 involved in human glioblastoma. Genes Chromosomes Cancer 1995; 12:255-261.
46. Steck PA, Perhouse MA, Jasser SA, et al: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 1997; 15:356-362.
47. Weiner HL: The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 1995; 37:179-194.
48. Wullich B, Sattler H, Fischer U, Meese E: Two independent amplification events on chromosome 7 in glioma: amplification of the epidermal growth factor receptor gene and amplification of the oncogene MET. Anticancer Res 1994; 14:577-580.
49. WongAJ, Bigner SH, Bigner DD, et al: Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sei USA 1987; 84:6899-6903.
50. Torp SH, Helseth E, Ryan L, et al: Amplification of the epidermal growth factor receptor gene in human gliomas. Anticancer Res 1991 ; 11:2095-2098.
51. Schlegal J, Merdes A, Stumm G, et al: Amplification of the epidermal-growth-factor-receptor gene correlates with different growth behavior in human glioblastoma. Int J Cancer 1994; 56:72-77.
52. Nishikawa R, Ji X, Harmon RC, et al: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sei USA I994; 91:7727-7731.
53. Ekstrand AJ, Sugavva N, James CD, Collins VP: Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N-and/or C-terminal tails. Proc Natl Acad Sei USA 1992; 89:43091313.
54. Yamazaki H, Ohba Y, Tamaoki N, Shibuya M: A deletion mutation within the ligand binding domain is responsible for activation of epidermal growth factor receptor gene in human brain tumors. Jpn J Cancer Res 1990; 81:773-779.
55. Kurpad SN, X.-G Z, Wikstrand CJ, et al: Tumor antigens in astrocytic gliomas. Glia 1995; 15:244-256.
56. Fearon ER, Cho KR, Nigro JM, et al: Identification of a chromosome 18q that is altered in colorectal cancers. Science 1990; 247(4938):49-56.
57. Reyes-Mugica M, Rieger-Christ K, Ohgaki H, et al: Loss of DCC expression and glioma progression. Cancer Res 1997; 57:382-386.
58. Sehgal A, Keener C, Boynton A, et al: Isolation and characterization of a novel gene from human glioblastoma multiforme tumor tissue. Int J Cancer 1997; 71:565-572.
59. Sehgal A, Keener C, Boynton A, et al: Characterization of C4-2 as a tumor-suppressor gene in human brain tumors. J Surg Oncol 1997; 64:102-108.
60. Sehgal A, Ricks S, Keener C, et al: Cloning, sequence, and developmental expression analysis of C4-2, a potential brain tumor-suppressor gene. J Surg Oncol 1997; 65:249-257.
61. Nicolson GL, Dulski KM, Trosko JE: Loss of intercellular junctional communication correlates with metastatic potential in mammary adenocarcinoma cells. Proc Natl Acad Sei USA 1988; 85:473-476.
62. Zhu D, Caveney S, Kidder GM, et al: Transfection of C6 glioma cells with connexin 43 cDNA: analysis of expression, intercellular coupling, and cell proliferation. Proc Natl Acad Sei USA 1991; 88:1883-1887.
63. Chen SC, Pelletier DB, Ao P, Boynton AL: Connexin43 reverses the phenotype of transformed cells and alters their expression of cyclin/cyclin-dependent kinases. Cell Growth Differ 1995; 6:681-690.
64. Shinoura N, Chen L, Wani MA, et al: Protein and messenger RNA expression of connexin43 in astrocytomas: implications in brain tumor gene therapy. J Neurosurg 1996; 84:839-846.
65. Wullich B, Muller H, Fischer U, et al: Amplified MET gene linked to double minutes in human glioblastoma. Eur J Cancer 1993; 29A: 1991-1995.
66. Muleris M,-Almeida A, Dutrillaux AM, et al: Oncogene amplification in human gliomas: a molecular cytogenetic analysis. Onco-' gene 1994; 9:2717-2722.
67. Yamada N, Mitsuyasu K, Yamashita H, et al: Enhanced expression of transforming growth factor-beta and its type-I and typeII receptors in human glioblastoma. Int J Cancer 1995; 62: 386-392.
68. Okada H, Yoshida J, Sokabe M, et al: Suppression of CD44 expression decreases migration and invasion of human glioma cells. Int J Cancer 1996; 66:255-260.
69. Takano S, Yoshii Y, Kondo S, et al: Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. Cancer Res 1996; 56:2185-2190.
70. Izumoto S, Ohnishi T, Arita N, et al: Gene expression of neural cell adhesion molecule LI in malignant gliomas and biological significance of LI in glioma invasion. Cancer Res 1996; 56:1440-1444.
71. Jung J, Bruner JM, Ruan S,etal: Increased levels of p21WAFI/Clpl in human brain tumors. Oncogene 1995; 11:2021-2028.
72. Zagzag D, Friedlander DR, Miller DC, et al: Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995; 55:907-914.
73. Cobbs CS, Brenman JE, Aldape KD, et al: Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 1995; 55:727-730.
74. Rempel SA, Rosenblum ML, Mikkelson T, et al: Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 1994; 54:6027-6031.
75. Yamamoto M, Mohanam S, Sawaya R, et al: Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996; 56:384-392.
76. Nakano A, Tani E, Miyazaki K, et al: Matrix metalloproteinases and tissue inhibitors of metalloproteinases in human gliomas. J Neurosurg 1995; 83:298-307.
77. Debinski W, Obiri NI, Powers SK, et al: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and psuedomonas exotoxin. Clin Can Res 1995; 1:1253-1258.
78. Lachyanker MB, Ross AH, Litofsky S, et al: TrkA expression decreases the in vivo aggressiveness of C6 glioma cells. Cancer Res 1997; 57:532-536.
79. Yamamoto M, Sawaya R, Mohanam S, et al: Expression and localization of urokinase- type plasminogen activator receptor in human gliomas. Cancer Res 1994; 54:5016-5020.
80. Wei Q, Bondy ML, Mao L, et al: Reduced expression of mismatch repair genes measures by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 1997; 57:1673-1677.
81. Chintala SK, Sawaya R, Lèvent Z, et al: Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro. Cancer Lett 1996; 101:107-114.
82. Hitotsumatsu T, Iwaki T, Fukui M, Tateshi J: Distinctive immunohistochemical profiles of small heat shock proteins (heat shock protein 27 and alpha B-crystallin) in human brain tumors. Cancer 1996; 77:352-361.
83. Previtali S, Quattrini A, Nemni R, et al: AIpha64 and alphaöl integrins in astrocytomas and other CNS tumors. J Neuropathol Expl Neurol 1996; 55:456-465. .